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of participants with HIV-associated tuberculosis starting antiretroviral treatment from a prospective trial
evaluating prednisone for TB-IRIS prevention, we applied latent class analysis to model a gold standard
for TB-IRIS. The model-predicted probability of TB-IRIS for each participant was used to assess the
performance of the INSHI case definition and compare its diagnostic accuracy with several adapted case
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Background: The diagnosis of paradoxical tuberculosis–associated
immune reconstitution inflammatory syndrome (TB-IRIS) relies on
characteristic clinical features synthesized as the International Network
for the Study of HIV-associated IRIS (INSHI) case definition. There is no
confirmatory laboratory test.
Setting: Site B HIV-TB clinic in Khayelitsha, Cape Town, South
Africa.
Methods: Using data of participants with HIV-associated tubercu-
losis starting antiretroviral treatment from a prospective trial
evaluating prednisone for TB-IRIS prevention, we applied latent
class analysis to model a gold standard for TB-IRIS. The model-
predicted probability of TB-IRIS for each participant was used to
assess the performance of the INSHI case definition and compare its
diagnostic accuracy with several adapted case definitions.
Results: Data for this analysis were complete for 217 participants;
41% developed TB-IRIS. Our latent class model included the
following parameters: respiratory symptoms; night sweats; INSHI
major criteria 1, 2, and 4; maximum C-reactive protein .90 mg/L;
maximum heart rate .120/min; maximum temperature .37.7°C;
and preantiretroviral therapy CD4 count ,50 cells/mL. The model
estimated a TB-IRIS incidence of 43% and had optimal goodness of
fit (x2 = 337, P = 1.0). The INSHI case definition displayed a
sensitivity of 0.77 and a specificity of 0.86. Replacing all the minor
INSHI criteria with objectives measures (C-reactive protein eleva-
tion, fever, and/or tachycardia) resulted in a definition with better
diagnostic accuracy, with a sensitivity of 0.89 and a specificity
of 0.88.
Conclusion: The INSHI case definition identifies TB-IRIS with
reasonable accuracy. Amending the case definition by replacing
INSHI minor criteria with objective variables improved sensitivity
without loss of specificity.
Key Words: tuberculosis, HIV, immune reconstitution inflamma-
tory syndrome, TB-IRIS, latent class analysis
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INTRODUCTION
Paradoxical tuberculosis–associated immune reconsti-
tution inflammatory syndrome (TB-IRIS) is an immunopath-
ological reaction resulting in new or recurrent TB signs and
symptoms, shortly after starting antiretroviral therapy (ART).
It complicates treatment of HIV-associated tuberculosis (TB)
in approximately 18% of cases, with rates more than 50% in
high risk groups, causing significant morbidity.1,2 The
diagnosis of TB-IRIS is largely based on its characteristic
clinical presentation; there is no confirmatory laboratory test.
The International Network for the Study of HIV-associated
IRIS (INSHI) consensus case definition is used to diagnose
TB-IRIS.3 It requires a diagnosis of TB with an initial
positive response to treatment, characteristic clinical features
(such as new or enlarging lymphadenopathy, constitutional,
respiratory or abdominal symptoms, or new or worsening
radiological features), and exclusion of alternative explana-
tions for clinical deterioration—see Supplemental Digital
Content, http://links.lww.com/QAI/B582. It is designed for
use by both clinicians and researchers in a variety of settings
and has been validated in several studies.4–6 However, in the
absence of a gold standard, validation was always performed
against diagnostic assignment based on expert opinion.
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Having a gold standard for TB-IRIS would allow for a more
objective validation of the INSHI case definition and
assessment of the ability of new variables to improve its
diagnostic accuracy.
Latent class analysis (LCA) is a modeling technique
that can identify unobserved groups, or classes, in a
population. It has been used and shown utility in several
diseases characterized by the lack of a gold standard, such as
latent TB or sepsis.7–11 LCA divides the population in 2
groups: those who have the disease and those who do not
have the disease. In the absence of a diagnostic standard for
the disease, the disease itself cannot be measured directly.
Instead, many clinical signs and symptoms exist, that are each
in themselves imperfect predictors of the disease. These signs
and symptoms cluster in different patterns in different
individuals. The observed frequencies of these patterns allow
for the construction of models estimating the prevalence of
the disease and the sensitivity and specificity of each sign or
symptom, or combinations thereof.
We used LCA to generate a surrogate gold standard for
TB-IRIS. Next, we used the LCA-predicted probability of
TB-IRIS for each participant to assess the performance of the
INSHI case definition and compare its diagnostic accuracy
with several adapted case definitions. We assessed the ability
of additional variables to improve the diagnostic accuracy of
the case definition. Finally, we assessed the ability of
C-reactive protein (CRP) as a rule-out test for TB-IRIS.
METHODS
Main Trial and Setting
We performed a retrospective analysis of data collected
in the PredART trial.12 This randomized, double-blind,
placebo-controlled trial showed that a 28-day course of
prophylactic prednisone in adult patients identified as being
at a high risk (time between initiation of antituberculosis
treatment and ART , 30 days; CD4 count £100 cells/mL) for
paradoxical TB-IRIS reduced the incidence of paradoxical
TB-IRIS, without an excess of adverse events. Between
August 2013 and February 2016, the trial enrolled 240
participants from Khayelitsha, Cape Town, South Africa.
Their median age was 36, 60% were men, and their median
CD4 count was 49 cells/mL. The primary endpoint of the trial
was the development of TB-IRIS, which was adjudicated by a
committee of 3 clinical experts not active at the clinical site
who were given access to all clinical, laboratory data, and
digital chest radiographs (CXR) and reports of other radio-
graphic studies. They also accessed TB-IRIS narrative
summaries that were written by the trial doctor for any
clinical deterioration after initiation of ART. After completion
of the trial, committee members independently assessed all
available information from each participant who experienced
clinical deterioration after initiation of ART. The INSHI
consensus case definition was used to diagnose TB-IRIS
(INSHI TB-IRIS). In addition, committee members were
given the option to indicate when they considered that a
participant developed TB-IRIS, although not fulfilling the
INSHI case definition (paradoxical TB-IRIS not fulfilling the
INSHI criteria); these participants were included in the
analyses and defined as not having TB-IRIS according to
INSHI criteria. Cases where there was disagreement, were
resolved by consensus between the members.
Selection of Variables
As variables for our latent class model, we included the
following: baseline participant characteristics (sex, age, and
details about current and previous TB episodes); INSHI major
criteria; all individual symptoms of the INSHI minor criteria;
any additionally documented signs and symptoms provided they
occurred in more than 10 (4%) participants and could feasibly be
related to TB-IRIS; baseline (immediately before starting ART)
and follow-up laboratory variables (hemoglobin, leucocytes,
creatinine clearance, alanine transferase, alkaline phosphatase,
CRP, CD4 count, and HIV viral load); signs and symptoms that
were identified as possibly related to TB-IRIS during the TB-
IRIS adjudication process; and baseline urine lipoarabino-
mannan (LAM), determined retrospectively on stored urine
using Alere Determine lateral flow assay.
Data for variables included were restricted to the first 4
weeks after ART initiation (95% of the TB-IRIS cases in our
cohort occurred within 4 weeks, with a median time between
ART initiation and TB-IRIS of 8 (interquartile range 5–13) days).
In LCA as we applied it, variables need to be binary; a
sign or symptom was either present or absent in the first 4
weeks. Therefore, continuous variables were transformed into
binary ones by plotting them in a receiver operating
characteristics (ROC) curve and—after excluding variables
with ROC area under the curve ,0.55—selecting a cut-off
that obtained the maximum of the sum of the computed
sensitivities and specificities. For these variables to be
positive, the highest [or, for hemoglobin (Hb) the lowest]
value of that variable measured anytime during the first 4
weeks needed to be higher (lower for Hb) than the cut-off.
Given the relatively small number of participants in the
study, only a limited number of variables could be included in
the LCA model to avoid overfitting the model to the data.
To select which variables to include in the latent class
model, we first calculated the unadjusted odds ratio (OR) for
each individual variable and the consensus decision of the
adjudication committee for INSHI TB-IRIS, using Stata version
14.2. These are listed in Table 1. We combined the abdominal
symptoms associated with TB-IRIS into one new variable, that
comprised “abdominal pain with either hepatomegaly, spleno-
megaly, or abdominal lymph nodes, or abdominal tenderness on
clinical examination without other explanation.” We combined
cough, dyspnea, and chest pain into the variable “respiratory
symptoms.” Both new variables did not affect the selection of
any other variable for inclusion in the latent class model.
We assessed different unadjusted ORs as cut-off for
variable inclusion in the multivariable model: OR .2.0 or
,0.5 (2-model), OR .3.0 or ,0.3 (3-model), and OR .5.0
or ,0.2 (5-model). We chose the 3-model because it was the
most parsimonious.
We did not include urine LAM in the initial latent class
model because of a higher number of participants with
missing data (n = 35). Rather, we used a model containing
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urine LAM as an alternative model to compare findings with
our final model.
Next, we combined variables selected based on their
unadjusted OR in a backward multiple logistic regression
model. Those variables with a P-value , 0.1 were retained
and entered in the latent class model, together with the INSHI
major criteria. The LCA model was limited to a maximum of
10 variables to avoid too many variable combinations with no
or very few observations. This limits the number of
observations to 9 per variable, in line with the recommenda-
tion to limit the number of variables in a logistic regression
model to 1 per 10 cases.13
Latent Class Model
We performed LCA using LEM software [J. Vermunt,
Tilburg, The Netherlands, 1993; https://jeroenvermunt.nl].
TABLE 1. Variables Initially Included in the Selection for the
Latent Class Model, Their Unadjusted Odds Ratio for
Paradoxical INHSI IRIS, and Their Occurrence in Participants













Sex (M) 0.8 56 (63%) 76 (59%)
Age (,40 y) 2.1 67 (75%) 76 (59%)
Previous tuberculosis 0.9 8 (9%) 14 (11%)
Microbiological evidence
of tuberculosis
1.8 71 (80%) 89 (70%)
Time from start of
tuberculosis treatment
to start of ART (,14d)
0.9 85 (96%) 89 (70%)
Baseline CD4 count
(,50 cells/mL)
3.5 70 (79%) 62 (48%)
Baseline HIV viral load
(,150,000 cp/mL)
1.0 12 (14%) 38 (30%)
Baseline urine LAM
($1)
4.0 62 (73%) 45 (38%)
INSHI-related variables
Major criteria
Enlarged lymph nodes — 30 (34%) 0 (0%)
New/worsening
radiological features
— 40 (45%) 0 (0%)
CNS TB-IRIS* — 0 (0%) 0 (0%)
New/worsening
serositis
— 3 (3%) 0 (0%)
Minor criteria
Weight loss† 4.0 45 (51%) 27 (21%)
Fever‡ 8.7 33 (37%) 8 (6%)
Night sweats 8.4 50 (56%) 14 (11%)
Anorexia 3.2 47 (53%) 32 (25%)
Weakness 3.8 30 (34%) 13 (10%)
Cough 3.9 32 (36%) 16 (13%)
Chest pain 6.4 24 (27%) 8 (6%)






4.3 8 (9%) 3 (2%)
Included other adverse
events§
Headache 3.8 22 (25%) 11 (9%)
Dizziness 0.5 6 (7%) 10 (13%)
Arthralgia 1.1 6 (7%) 8 (6%)
Back pain 0.6 4 (4%) 8 (6%)
Flank pain 1.3 5 (6%) 5 (4%)
Epigastric pain 1.5 5 (6%) 5 (4%)
Abdominal pain 4.5 20 (22%) 8 (6%)
Nausea 2.8 27 (30%) 17 (13%)
Vomiting 2.5 34 (38%) 25 (20%)
Diarrheak 4.3 28 (31%) 9 (7%)
Herpes simplex
infection
2.2 17 (19%) 13 (10%)
TABLE 1. (Continued ) Variables Initially Included in the
Selection for the Latent Class Model, Their Unadjusted Odds
Ratio for Paradoxical INHSI IRIS, and Their Occurrence in
Participants With and Without Paradoxical TB-IRIS According











Pruritis 1.1 6 (7%) 7 (5%)
Paresthesia 0.9 7 (8%) 10 (8%)
Papular pruritic
eruption





4.9 62 (70%) 39 (30%)
Return of any (non-
INSHI) initial
tuberculosis symptom




14.9 9 (10%) 1 (1%)
Raised CRP 5.7 55 (62%) 27 (21%)
Laboratory variables¶
Hemoglobin (,10 g/dL) 2.0 52 (58%) 51 (39%)
Leukocytes (.10 · 109
cells/L)
1.0 33 (37%) 11 (9%)
CRP (.90 mg/L) 5.7 55 (62%) 27 (21%)
Unadjusted ORs were computed including all participants of the PredART trial who
had taken at least one dose of ART. Comparison between participants with and without
paradoxical TB-IRIS was performed in participants included in the latent class model.
*None of the participants developed neurological TB-IRIS.
†Weight loss is defined as . 2.5% in 2 weeks or . 5% in 4 weeks.
‡Fever is defined as temperature . 37.7°C, following the DAIDS table for grading
the severity of adverse events that was current during the collection of data.
§The following adverse events were excluded from analysis because of an unlikely
association with TB-IRIS: upper respiratory tract infection (including coryza), blocked
nose, ear symptoms, tooth ache, heartburn, hemorrhoids, swollen feet, a patient history
of feeling hot or cold, scabies, urinary tract infection, and low potassium.
║This includes both diarrhea and “more frequent than normal loose stools.”
¶The following laboratory variables were excluded from analysis because the area
under the curve in the receiver-operating characteristic curve was , 0.55: creatinine
clearance, alanine transferase, alkaline phosphatase, increase in CD4 count at week 12,
and decrease in HIV viral load at week 12.
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We assumed the presence of 2 latent classes, corresponding to
TB-IRIS and no TB-IRIS. We initially fitted models applying
the conditional independence assumption. Goodness of fit
tests—using the x2 test—confirmed there was no requirement
to include conditional dependencies between variables in the
LCA model. We excluded 21 participants with missing data
on any of the selected variables because LEM does not allow
missing values. Baseline variables for these participants were
comparable with those of the included participants (data
not shown).
Diagnostic Accuracy of Various Case
Definitions and CRP
After running the latent class model, we used the LCA-
predicted probability of TB-IRIS for each participant to first
calculate the positive and negative predictive values for each
sign or symptom initially considered for LCA, followed by
their sensitivity and specificity, again using Stata version
14.2. We combined the individual signs and symptoms to
match the INSHI consensus case definition or form several
adapted case definitions. Doing so, we could assess the
performance of the INSHI case definition and compare its
diagnostic accuracy with the adapted case definitions. We
also assessed the diagnostic ability of CRP to rule-out TB-
IRIS, using a range of lower cut-off values, aiming for a
high sensitivity.
RESULTS
Of the 240 participants in the PredART trial, complete
data for latent class modeling were available for 217
participants (see Figure 1, Supplemental Digital Content,
http://links.lww.com/QAI/B581). Baseline variables for these
217 were comparable with those of all participants in the
PredART trial (data not shown).
Presentation of Paradoxical TB-IRIS
Eighty-nine participants (41%) developed TB-IRIS
according to the INSHI criteria. Twelve (6%) participants
were adjudicated by the committee to have paradoxical TB-
IRIS not fulfilling the INSHI criteria. Of the INSHI TB-IRIS
cases, 66 (74%) fulfilled at least one INSHI major criterion,
criteria 1 and 2 (new or enlarging lymph nodes or new or
worsening chest CXR abnormalities) being the most frequent.
None of the participants fulfilled INSHI major criterion 3
(neurologic features). All but one of the participants who
developed TB-IRIS also fulfilled at least one minor criterion.
Twenty-three participants (26%) had a diagnosis of TB-IRIS
based on having 2 or more minor criteria without a major
criterion. Of the participants without TB-IRIS, 26 (20%)
fulfilled 1 minor criterion; this included all 12 participants
assessed by the committee to have paradoxical TB-IRIS, but
not fulfilling the INSHI criteria.
The most frequent symptoms in participants with
INHSI TB-IRIS were respiratory symptoms (65%), night
sweats (56%), loss of appetite (53%), and loss of weight
(51%) followed by vomiting (38%), diarrhea or loose stool
(31%), and weakness (34%). Fever (temp . 37.7°C) was
present in 37% of the participants with INSHI TB-IRIS and
tachycardia (heart rate . 120/min) in 70%. Sixty-two percent
had a CRP . 90 mg/L (Table 1).
Latent Class Model
The final latent class model included 9 variables:
respiratory symptoms, night sweats, INSHI major criteria 1,
2, and 4 (new or enlarging lymph nodes, radiological
abnormalities, and serositis, respectively), maximum CRP
.90 mg/L, maximum heart rate .120/min, maximum
temperature .37.7°C, and pre-ART CD4 count ,50 cells/
mL. The model showed a good fit to the data (x2 = 337, P =
1.0). The model-estimated incidence of TB-IRIS was 43%.
The predicted sensitivities and specificities of the variables
included in the model are summarized in Table 2. Other
models, for example, a model with the 5-model selected
variables, a model including baseline urine LAM instead of
maximum CRP, or a model including weight loss instead of
fever showed similar results to the selected model (see Table
1, Supplemental Digital Content, http://links.lww.com/QAI/
B581).
Comparison of Case Definitions
Using the model-predicted probability of TB-IRIS for
each participant, we found the INSHI consensus case
definition had a sensitivity of 0.77 and a specificity of 0.86.
We constructed several adapted case definitions, replacing
one or 2 of the required INSHI minor criteria with one or
more of the model-derived variables CRP (.90 mg/L), heart
rate (.120/min), or fever (temperature . 37.7°C). The
adapted case definitions had sensitivities and specificities
similar to the INSHI consensus case definition. A definition
replacing all the minor criteria with objective measures (CRP
elevation, fever, and/or tachycardia) showed better diagnostic
accuracy, with a sensitivity of 0.89 and a specificity of 0.88.
Performance of the INSHI case definition and the adapted
case definitions to identify TB-IRIS is summarized in Table 3.
TABLE 2. LCA-Predicted Sensitivity and Specificity of Variables






Respiratory symptoms 0.57 0.79
Night sweats 0.58 0.91
INSHI major 1 (new or enlarging
lymph nodes)
0.28 0.96
INSHI major 2 (new or worsening
CXR abnormalities)
0.38 0.96
INSHI major 4 (new or worsening
serositis)
0.02 0.99
Maximum CRP . 90 mg/L 0.73 0.88
Maximum heart rate .120 bpm 0.79 0.78
Maximum temperature .37.7°C 0.44 1.00
Nadir CD4 count ,50 cells/mL 0.81 0.54
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CRP to Rule out TB-IRIS
Using the model-predicted probability of TB-IRIS for
each participant, we found CRP values of . 10 mg/mL to .
50 mg/mL all had a sensitivity above 0.9 and a negative
likelihood ratio of # 0.15 (indicating a moderate to large
decrease in probability of having a CRP value lower than the
cut-off when having TB-IRIS) (see Table 2, Supplemental
Digital Content, http://links.lww.com/QAI/B581). The area
under the ROC curve was 0.86. The association between CRP
and likelihood of TB-IRIS is shown in Figure 1, showing the
inverse likelihood ratio, which indicates how many times less
likely each CRP value is associated with TB-IRIS. We
repeated the analysis using an alternative model including
baseline urine LAM instead of CRP to confirm our findings;
this analysis showed similar results (data not shown).
DISCUSSION
Because of the lack of a gold standard, validation of the
INSHI consensus case definition for paradoxical TB-IRIS has
previously been performed against diagnostic assignment
based on expert opinion4,5 or another expert opinion–based
case definition,6 showing sensitivities of 0.72–0.91 and
specificities of 0.93–1.0. We applied LCA, using participant
data from a prospective trial of a TB-IRIS prevention strategy,
to provide a surrogate gold standard for TB-IRIS. Participants
included in this trial were all coinfected with HIV and TB and
starting ART. This surrogate gold standard enabled us to
validate the INSHI consensus case definition and confirm its
reasonable diagnostic accuracy found in the previous studies
using a data-derived approach.
The INSHI consensus case definition consists of 3
components: a prerequisite of a diagnosis of TB with an
initial positive response to treatment, clinical features sum-
marized in a combination of major and minor criteria, and
exclusion of other reasons for clinical deterioration. The first
and the last component are largely unambiguous. However,
many of the INSHI minor criteria have a subjective compo-
nent and depend on patient-reported symptoms. Replacing
these with objective variables could make the definition more
robust and improves uniformity, which is advantageous if the
definition is to be used for endpoint definition in clinical
trials. We found that amending the case definition by
replacing the INSHI minor criteria with the more objective
variables tachycardia, fever, and/or CRP elevation improved
sensitivity without loss of specificity.
CRP in itself may have utility as a rule-out test for TB-
IRIS. We assessed this diagnostic ability of CRP and found
that a normal CRP (,10 mg/L) can be used to rule out
FIGURE 1. The association between CRP and likelihood of TB-
IRIS. CRP (mg/L) is plotted against the inverse likelihood ratio
of TB-IRIS, as predicted by the latent class model. The inverse
likelihood ratio indicates how many times less likely each CRP
value is associated with TB-IRIS.
TABLE 3. Diagnostic Accuracy of INSHI and Adapted Case
Definitions
TB-IRIS Definition Sensitivity Specificity LR+ LR2
INSHI case definition: Presence of at
least
0.77 0.86 5.50 0.27
1 INSHI major criterion OR
2 INSHI minor criteria
CRP .90 mg/L 0.73 0.88 6.08 0.31
Baseline urine LAM $1 0.76 0.67 2.30 0.36
Presence of at least 1 INSHI major
criterion alone
0.60 0.92 7.50 0.43
Presence of at least 0.85 0.78 3.86 0.19
1 INSHI major criterion OR
2 INSHI minors criteria OR
1 INSHI minor criterion and
CRP .90 mg/L
Presence of at least 0.86 0.83 5.06 0.17
1 INSHI major criterion OR
1 INSHI minor criterion and
CRP .90 mg/L
Presence of at least 0.93 0.82 5.17 0.09
1 INSHI major criterion OR





Presence of at least 0.89 0.88 7.42 0.13
1 INSHI major criterion OR




Case definitions were constructed, and their sensitivity, specificity, and positive and
negative likelihood ratios computed using the LCA-predicted probability of TB-IRIS for
each participant.
LR+, positive likelihood ratio; LR2, negative likelihood ratio.
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TB-IRIS. Because most patients with HIV-associated TB will
however have a CRP . 10 mg/L,14–16 we also assessed
higher CRP cut-offs. Figure 1 showed that especially a low
CRP is useful in excluding TB-IRIS, but higher cut-off values
of CRP still have an added value in ruling-out TB-IRIS. A
CRP value of 82.4 corresponds to the cut-off that is equally
likely for patients with or without TB-IRIS.
Our study has several limitations: first, a relatively small
study cohort and inclusion of a large number of possible
variables in the latent class model resulted in the need to
preselect variables based on their univariate association with
TB-IRIS so as not to exceed 10 variables in the model.
Consequently, some important variables may have been
excluded. However, we explored different selection criteria
which resulted in similar results giving assurance of the
robustness of the model. Second, there were no participants
with a temperature above 37.7°C among those who were
classified as not having TB-IRIS according to the latent class
models. Leaving temperature out of the model did not affect
this finding. Looking at the raw data, however, only 4 of the 41
participants with a temperature above 37.7°C did not have TB-
IRIS, according to either the INSHI case definition or the
adjudication committee; all 4 had a more likely alternate
diagnosis (gastrointestinal infection, drug resistant TB, drug
rash, and drug-induced liver injury). Third, in the PredART
trial, CXRs were only repeated on ART when suspected TB-
IRIS or other clinical deterioration prompted the clinician to
request a CXR. As a consequence, we do not have documented
normal CXRs for all participants who did not develop TB-
IRIS, and therefore cannot say with certainty that none of the
participants in this group had new or worsening CXR features.
However, in the absence of other symptoms, one can question
its clinical relevance. Fourth, this was a restricted patient
population, purposefully selected for its high risk of TB-IRIS;
only patients with a CD4 count #100 cells/mL and antituber-
culosis treatment for ,30 days before starting ART were
included in the trial. It could be our model performs differently
in a population with a lower incidence of TB-IRIS. Moreover,
our findings only apply to patients with HIV-associated TB
starting ART and not to paradoxical reactions that may occur in
HIV-negative patients undergoing immune reconstitution for
other reasons. Fifth, the method we used allows for only the
estimation of the diagnostic indicators of variables included in
the model and other variables. Calculation of the uncertainty
and resulting confidence intervals of these estimates is however
complex and is hampered by the inherent multiplicity because
of variable selection in LCA model building. For this reason,
we did not estimate confidence intervals for diagnostic
accuracy measures in this analysis. Consequently, these
estimates should be seen as exploratory and will need
validation in an independent data set to correctly estimate the
bias and uncertainty in these estimates.
In conclusion, we found that the INSHI case definition
identifies TB-IRIS with reasonable accuracy. Amending the
case definition by replacing the INSHI minor criteria with the
objective variables tachycardia, fever, and/or CRP elevation
improved sensitivity without loss of specificity in a popula-
tion at a high risk of TB-IRIS. We recommend that in future
studies on TB-IRIS a version of the INSHI case definition
with objective measures be used, next to the traditional case
definition. CRP seems to be promising as a test for ruling
out TB-IRIS.
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